Efficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.

To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.

Wound Gel Formulations Containing Poloxamer 407 and Polyhexanide Have Antimicrobial and Antibiofilm Activity Against Wound-Associated Microbial Pathogens.

Chronic wounds are often caused or exacerbated by microbial biofilms that are highly resistant to antimicrobial treatments and that prevent healing. This study compared the antimicrobial and antibiofilm activity of nine topical wound treatments, comprising gels with different concentrations of poloxamer 407 (20-26%) and different pH levels (4-6) and containing polyhexanide (PHMB) as an antimicrobial agent; the effects of pH on wound gels containing this agent have not been previously reported. The wound gel formulations were tested against six common wound-associated microbial pathogens: , , , , , and .

Occurrence and risk assessment of polybrominated diphenyl ethers in surficial water and sediment from Buffalo River estuary, South Africa.

This study assessed PBDE congeners in surface water and sediment from the Buffalo River estuary, East London, South Africa. Samples were collected across three seasons in 2020 and analyzed using GC-MS and GC-μECD to respectively identify and quantify analytes. The concentration of ∑PBDEs in the surface water and sediment ranged from n.